X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (46) 46
female (36) 36
oncology (33) 33
middle aged (31) 31
aged (26) 26
breast neoplasms - drug therapy (25) 25
breast cancer (17) 17
adult (15) 15
male (14) 14
index medicus (13) 13
chemotherapy (11) 11
aged, 80 and over (10) 10
breast neoplasms - pathology (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
drug administration schedule (8) 8
further section (8) 8
antineoplastic agents - therapeutic use (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
chemotherapy, adjuvant (7) 7
disease-free survival (7) 7
postmenopause (7) 7
randomized-trial (7) 7
tamoxifen (7) 7
time factors (7) 7
treatment outcome (7) 7
adjuvant therapy (6) 6
breast neoplasms - surgery (6) 6
cancer (6) 6
docetaxel (6) 6
postmenopausal women (6) 6
prognosis (6) 6
anastrozole (5) 5
aromatase inhibitors (5) 5
breast neoplasms - mortality (5) 5
clinical trials (5) 5
methotrexate - administration & dosage (5) 5
pharmacology & pharmacy (5) 5
tamoxifen - adverse effects (5) 5
ultrasonography (5) 5
antineoplastic agents, hormonal - adverse effects (4) 4
antineoplastic agents, hormonal - therapeutic use (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
breast neoplasms - therapy (4) 4
carboplatin - administration & dosage (4) 4
combined modality therapy (4) 4
endometrium - diagnostic imaging (4) 4
endometrium - drug effects (4) 4
endometrium - pathology (4) 4
exemestane (4) 4
fluorouracil - administration & dosage (4) 4
hematology, oncology and palliative medicine (4) 4
letrozole (4) 4
lymphatic metastasis (4) 4
metastasis (4) 4
neoplasm metastasis (4) 4
neoplasm staging (4) 4
neoplasms, hormone-dependent - drug therapy (4) 4
survival (4) 4
survival rate (4) 4
tamoxifen - therapeutic use (4) 4
therapy (4) 4
androstadienes - adverse effects (3) 3
androstadienes - therapeutic use (3) 3
antineoplastic agents (3) 3
apoptosis (3) 3
aromatase inhibitors - therapeutic use (3) 3
bisphosphonate (3) 3
bone neoplasms - secondary (3) 3
breast (3) 3
cancer research (3) 3
cancer therapies (3) 3
care and treatment (3) 3
cells (3) 3
cyclophosphamide - administration & dosage (3) 3
double-blind (3) 3
doxorubicin (3) 3
drug evaluation (3) 3
efficacy (3) 3
endometrial cancer (3) 3
filgrastim (3) 3
follow-up studies (3) 3
lung neoplasms - drug therapy (3) 3
medicine & public health (3) 3
methotrexate (3) 3
neoplasms, hormone-dependent - pathology (3) 3
paclitaxel - administration & dosage (3) 3
paclitaxel - adverse effects (3) 3
patients (3) 3
phase-ii trial (3) 3
prospective studies (3) 3
prostatic neoplasms - pathology (3) 3
quality of life (3) 3
quality-of-life (3) 3
receptor, erbb-2 - metabolism (3) 3
research (3) 3
review (3) 3
tumors (3) 3
vinblastine - administration & dosage (3) 3
women (3) 3
adjuvant chemotherapy (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 5, pp. 549 - 558
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 929 - 945
Summary Background Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to... 
Hematology, Oncology and Palliative Medicine | Capecitabine - administration & dosage | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Breast Neoplasms, Male - surgery | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fatigue - chemically induced | Epirubicin - administration & dosage | Hand-Foot Syndrome - etiology | Diarrhea - chemically induced | Cyclophosphamide - adverse effects | Filgrastim | Infection - chemically induced | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Time Factors | Female | Neutropenia - chemically induced | Carcinoma - secondary | Carcinoma - drug therapy | Polyethylene Glycols | Carcinoma - surgery | Survival Rate | Neoplasm Recurrence, Local - diagnosis | Breast Neoplasms, Male - drug therapy | Breast Neoplasms - drug therapy | Recombinant Proteins - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Capecitabine - adverse effects | Breast Neoplasms - pathology | Chemotherapy, Adjuvant - methods | Quality of Life | Methotrexate - administration & dosage | Epirubicin - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage | Medical research | Care and treatment | Anthracyclines | Adjuvant treatment | Clinical trials | Breast cancer | Standards | Cyclophosphamide | Hospitals | Medicine, Experimental | Research institutes | Methotrexate | Health aspects | Cancer | Analysis
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 11/2015, Volume 154, Issue 1, pp. 209 - 210
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2004, Volume 350, Issue 11, pp. 1081 - 1092
Journal Article
European Journal of Surgical Oncology, ISSN 0748-7983, 03/2018, Volume 44, pp. S43 - S43
Journal Article
European Journal of Surgical Oncology, ISSN 0748-7983, 03/2018, Volume 44, pp. S43 - S43
Journal Article
European Journal of Surgical Oncology, ISSN 0748-7983, 03/2018, Volume 44, pp. S46 - S46
Journal Article
European Journal of Surgical Oncology, ISSN 0748-7983, 11/2017, Volume 43, Issue 11, pp. 2239 - 2240
Journal Article
European Journal of Surgical Oncology, ISSN 0748-7983, 11/2017, Volume 43, Issue 11, pp. 2242 - 2242
Journal Article
European Journal of Surgical Oncology, ISSN 0748-7983, 11/2017, Volume 43, Issue 11, pp. 2240 - 2240
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e17051 - e17051
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2018, Volume 36, Issue 19, pp. 1981 - 1990
PurposeThe role of temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy as a strategy to preserve ovarian... 
PROTECTION | ONCOLOGY | GNRH AGONIST | OUTCOMES | SUPPRESSION | YOUNG-WOMEN | TRIPTORELIN | PREGNANCY | Review
Journal Article
International Journal of Surgery, ISSN 1743-9191, 2013, Volume 11, Issue 8, pp. 607 - 607
Journal Article
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, ISSN 0027-8874, 08/2018, Volume 110, Issue 8, pp. 871 - 879
Background: Adjuvant therapies can prevent/delay bone metastasis development in breast cancer. We investigated whether serum bone turnover markers in early... 
CELLS | THERAPY | MODELS | ONCOLOGY | PROSTATE-CANCER | RANDOMIZED-TRIAL | OPEN-LABEL | TURNOVER MARKERS | PREMENOPAUSAL | OSTEOPOROSIS | ADJUVANT ZOLEDRONIC ACID
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.